Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs RLX Technology Inc (RLX) Price & Performance

Cassava Sciences IncTrade
RLX Technology IncTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs RLX Technology Inc — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while RLX Technology Inc trades at $2.02 (market cap $2.42B). The key difference: RLX Technology Inc is far larger — about 50.7× Cassava Sciences Inc's market cap, and RLX Technology Inc pays a 5.05% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

FLNARLX
Market Cap
$47.75M$2.42B
Sector
HealthTechnology
52-Week High
$4.64$2.73
52-Week Low
$0.87$1.79
Enterprise Value
-$34.93M$1.04B
Dividend Yield
5.05%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.9528, down 4.46% today, with a bearish technical outlook but strong analyst support (66.7% buy ratings). The company continues to post net losses and negative cash flows, though recent EPS beats show some operational improvement. Recent news highlights Q2 2026 results and business updates on Tuberous Sclerosis Complex therapies.

The outlook remains speculative due to persistent unprofitability and cash burn, but analyst optimism and a low P/B ratio of 0.75 may attract value investors. Key risks include execution challenges in drug development and reliance on financing amid negative earnings.

RLX Technology Inc

RLX Technology trades at $2.02, up 1.0% with bearish technical signals despite recent earnings misses. The company maintains strong profitability with 22.47% net margins and international expansion driving revenue growth from $3.62B to $4.4B. Cash flow trends show operational strength but negative net cash flow. Analyst coverage remains limited with a single hold rating.

RLX faces execution risks from international integration while trading at reasonable valuations (P/E 17.96). The upcoming Q2 2026 earnings on August 14 will be crucial for validating growth trajectory amid competitive and regulatory pressures in the global e-vapor market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About RLX Technology Inc

RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.

Read more on RLX